Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 170 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychomotor Agitation Clear all
Completed Phase 3 Interventional Results available

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

NCT00857727
View directory record Official record
Conditions
Agitation, Anesthesia, Pediatrics
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
6 Months to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 9, 2026, 8:29 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 9, 2026, 8:29 AM EDT
Completed No phase listed Observational

The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease

NCT01329536
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methodology Issues in a Tailored Light Treatment for Persons With Dementia

NCT01816152
View directory record Official record
Conditions
Sleep Disturbances, Depression
Interventions
High Active intervention, Inactive intervention, Mid Level Active Intervention
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Albany, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional Results available

Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

NCT01126099
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Prazosin, Placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 9, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional Results available

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
171
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 9, 2026, 8:29 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Peer Support in the ED (PCORI)

NCT06556069
View directory record Official record
Conditions
Psychomotor Agitation, Behavioral Disorder
Interventions
Peer-Support Enhanced Agitation Code Team (PACT)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
57,870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Withdrawn Phase 2 Interventional

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

NCT05313386
View directory record Official record
Conditions
Agitation, Delirium
Interventions
BXCL501, Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Completed No phase listed Observational

Ketamine Versus Midazolam for Prehospital Agitation

NCT03554915
View directory record Official record
Conditions
Agitation
Interventions
Ketamine-based protocol, Midazolam-based protocol
Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Results available

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

NCT02203019
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Agitation
Interventions
Propofol, Dexmedetomidine, Fentanyl
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome

NCT01617044
View directory record Official record
Conditions
Iron Deficiency, Restless Leg Syndrome
Interventions
Probiotics, Placebo
Dietary Supplement
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 9, 2026, 8:29 AM EDT
Terminated No phase listed Observational

Olanzapine Versus Midazolam for Agitation

NCT03899506
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Olanzapine, Midazolam
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 9, 2026, 8:29 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT07011745
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional Results available

Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit

NCT01848158
View directory record Official record
Conditions
Agitation
Interventions
acupuncture, sham acupuncture
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Bipolar Disorder

NCT00721955
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

NCT01862640
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

ADASUVE-Lorazepam Drug-Drug Interaction

NCT01877642
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lorazepam 1 mg IM, Inhaled loxapine 10 mg, Inhaled Placebo, Placebo IM
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT06546995
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Elderly
Interventions
NMRA-323511, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Chandler, Arizona • Tempe, Arizona • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Receptive Music Therapy in the ICU

NCT03931733
View directory record Official record
Conditions
Critical Illness
Interventions
Music Therapy
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Leesburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 9, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04464564
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
46
States / cities
Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Music Intervention for Agitation Reduction in the Pediatric Intensive Care Unit

NCT03453814
View directory record Official record
Conditions
Critical Illness
Interventions
Music Therapy
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
5 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 9, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Agitation in People With Dementia: the Customized Activity Trial

NCT01892579
View directory record Official record
Conditions
Dementia
Interventions
Tailored Activity Program, Home Safety and Education Program
Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 9, 2026, 8:29 AM EDT
Active, not recruiting Early Phase 1 Interventional

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT04075435
View directory record Official record
Conditions
Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
high CBD/low THC sublingual solution
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 9, 2026, 8:29 AM EDT
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

NCT06781333
View directory record Official record
Conditions
Alzheimer Disease, Agitation in Dementia
Interventions
hMSC
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 9, 2026, 8:29 AM EDT